Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders.

Trial Profile

Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Autoimmune disorders; Renal transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Jul 2012 Last checked against European Clinical Trials Database record.
    • 06 Mar 2010 Actual patient number (20) added as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top